Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 711

Sort by

Sort Order Select

Journal Articles

Disease Modeling of Severe Congenital Neutropenia Using CRISPR/Cas9 Gene Correction or Knockout of ELANE in Patients Derived Induced Pluripotent Stem Cells

Masoud Nasri, MSc, Benjamin Dannenmann, Perihan Mir, Malte U Ritter, Diana Amend, Yun Xu, Maksim Klimiankou, Cornelia Zeidler, Karl Welte, Julia Skokowa, MD PhD

Blood (2019) 134 (Supplement_1): 434.

https://doi.org/10.1182/blood-2019-129991

Published: 2019

Journal Articles

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Ryan J Caddell, PharmD, BCOP, Hayder Saeed, MD, Rebecca Nelson, PharmD, BCOP, Leidy Isenalumhe, MD, Julio Chavez, Celeste Bello, MD, Javier Pinilla Ibarz, MD PhD, Lubomir Sokol, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5292.

https://doi.org/10.1182/blood-2019-128435

Published: 2019

Journal Articles

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Blood (2019) 134 (Supplement_1): 4238.

https://doi.org/10.1182/blood-2019-126967

Published: 2019

Journal Articles

Outcomes of Isolated Neutropenia Referred to Pediatric Hematology Oncology Clinic

Vishnu Nagalapuram, MBBS, David McCall, MD, Prasannalaxmi Palabindela, MD, Christina Bemrich Stolz, MD, Thomas H. Howard, MD, Jeffrey D. Lebensburger, DO, MSPH, Lee Hilliard, MD

Blood (2019) 134 (Supplement_1): 5858.

https://doi.org/10.1182/blood-2019-126274

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Zeyad Al-Shaibani, MD, Eshrak AL-Shaibani, MD, Mats Remberger, PhD, Wilson Lam, MD, Arjun Law, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MD, Dennis Dong Hwan Kim, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 2046.

https://doi.org/10.1182/blood-2019-124208

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Blood (2019) 134 (Supplement_1): 4455.

https://doi.org/10.1182/blood-2019-127480

Published: 2019

Journal Articles

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Manju Sengar, MD DM, Mounika Boppana, MD DM, Hasmukh Jain, MD DM, Vikram Gota, MD, Bhausaheb Bagal, MD DM, Anant Gokarn, MD, Murari Gujrar, MD, Madhavi Ambotkar, MD

Blood (2019) 134 (Supplement_1): 2600.

https://doi.org/10.1182/blood-2019-129948

Published: 2019

Journal Articles

Association between GLUT1 and HbF Levels in Red Blood Cells from Patients with Sickle Cell Disease

Alireza Paikari, MD, Ankush Goyal, MA, Christelle Cousin, PhD, Vincent Petit, DVM, PhD, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 2265.

https://doi.org/10.1182/blood-2019-131058

Published: 2019

Journal Articles

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Jiasheng Wang, MD, Kirsten M Boughan, DO, Paolo F Caimi, MD, Brenda Cooper, MD, Marcos de Lima, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Shufen Cao, Pingfu Fu, PhD, Benjamin Tomlinson, MD

Blood (2019) 134 (Supplement_1): 2607.

https://doi.org/10.1182/blood-2019-131293

Published: 2019

Journal Articles

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Lydia Benitez, PharmD, Anthony J. Perissinotti, PharmD, Caitlin R. Rausch, PharmD, Jeff Klaus, PharmD, Stephen Michael Clark, PharmD, Michael Filtz, PharmD, Kelley L Ratermann, PharmD, Carissa F. Treptow, PharmD, Shawn Griffin, PharmD, Marissa Olson, PharmD, Mallory Crain, PharmD, Kristen Pettit, MD, Patrick W. Burke, MD, Dale L. Bixby, MD, Bernard Lawrence Marini, PharmD

Blood (2019) 134 (Supplement_1): 2639.

https://doi.org/10.1182/blood-2019-122189

Published: 2019

Journal Articles

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

Caitlin R. Rausch, PharmD, Courtney D. DiNardo, MDMSc, Abhishek Maiti, MBBS, Nadya Jammal, PharmD, Tapan M. Kadia, MD, Kayleigh Marx, PharmD, Gautam M. Borthakur, MD, J Michael Savoy, PharmD, Naveen Pemmaraju, MD, Adam Dipippo, PharmD, Naval G. Daver, MD, Serena Chew, PharmD, Koji Sasaki, MD, Ghayas C. Issa, MD, Kiran Naqvi, MDMPH, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2640.

https://doi.org/10.1182/blood-2019-131988

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Ann Dahlberg, MD, Muna Qayed, MDMSc, Katherine Tarlock, MD, Jessica A. Pollard, MD, Filippo Milano, MD PhD, Soheil Meshinchi, MD PhD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 2614.

https://doi.org/10.1182/blood-2019-130979

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Disease Modeling of Severe Congenital Neutropenia Using CRISPR/Cas9 Gene Correction or Knockout of ELANE in Patients Derived Induced Pluripotent Stem Cells

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Outcomes of Isolated Neutropenia Referred to Pediatric Hematology Oncology Clinic

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Association between GLUT1 and HbF Levels in Red Blood Cells from Patients with Sickle Cell Disease

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only